A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer.

Trial Profile

A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Casopitant (Primary) ; Docetaxel
  • Indications Chemotherapy-induced nausea and vomiting; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Aug 2011 Additional trial investigator (Cheri Hudson) identified as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Results published in Cancer Chemotherapy and Pharmacology.
    • 20 May 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top